ACY001, bone marrow-derived hematopoietic stem cells for treatment of critical limb ischemia

ACY001 is autologous, bone marrow-derived hemangioblast stem cells. This study aims to evaluate the safety of administration of marrow-derived autologous hematopoietic stem cells (HSC) concentrate and platelet-rich plasma (PRP) gel for the treatment of Critical Limb Ischemia (CLI).